View Older Stories View More Recent Stories

May 9, 2022 08:31AM RedHill Biopharma (RDHL) Announces 10.57M ADS Direct Offering at $1.42/ADS
May 9, 2022 08:30AM RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
Apr 11, 2022 09:01AM RedHill Biopharma (RDHL) Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
Apr 11, 2022 09:00AM RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro
Apr 11, 2022 08:03AM RedHill Biopharma (RDHL) Announces Potent Omicron Inhibition with RedHill's Opaganib
Apr 11, 2022 08:02AM RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib
Mar 17, 2022 07:59AM RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results
Mar 15, 2022 09:03AM RedHill Biopharma (RDHL) and Kukko Enter Oral Opaganib License for COVID-19 in South Korea
Mar 15, 2022 09:00AM RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea
Mar 10, 2022 07:00AM RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022
Mar 1, 2022 09:01AM RedHill Biopharma (RDHL) Reports Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Mar 1, 2022 09:00AM RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Feb 17, 2022 09:31AM RedHill Biopharma (RDHL) Reports Record Quarterly Revenues and First Commercial Operations Breakeven
Feb 17, 2022 09:30AM RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven
Feb 7, 2022 10:15AM RedHill Biopharma (RDHL) Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
Feb 7, 2022 10:15AM RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19
Jan 13, 2022 10:35AM RedHill Biopharma (RDHL) Reports Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
Jan 13, 2022 10:35AM RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients
Jan 6, 2022 09:16AM RedHill Biopharma (RDHL) Announces License Agreement with Gaelan Medical for Talicia in UAE
Jan 6, 2022 09:15AM RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
Dec 15, 2021 09:16AM RedHill Announces Additional Insider Buying
Dec 15, 2021 09:15AM RedHill Biopharma (RDHL) Announces Additional Insider Buying
Dec 15, 2021 09:15AM RedHill Biopharma Announces Additional Insider Buying
Dec 9, 2021 07:00AM RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication
Dec 6, 2021 07:05AM RedHill Biopharma (RDHL) Announces Opaganib MoA Not Impacted by Omicron Mutations
Dec 6, 2021 07:01AM RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations
Dec 6, 2021 07:00AM RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations
Dec 2, 2021 07:02AM RedHill Biopharma (RDHL) Announces Publication Showing Consistent Efficacy of Talicia Irrespective of Patient BMI
Dec 2, 2021 07:00AM RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI
Dec 1, 2021 07:27AM RedHill Biopharma (RDHL) Announces Movantik Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
Dec 1, 2021 07:22AM RedHill Biopharma's Movantik® Added as Preferred and Unrestricted Brand To Major National Medicare Formulary Serving Millions of Americans
Nov 30, 2021 07:02AM RedHill Reports 3Q/2021 Financial Results
Nov 30, 2021 07:00AM RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
Nov 24, 2021 07:00AM RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021
Nov 15, 2021 07:02AM RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
Nov 15, 2021 07:00AM RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
Nov 9, 2021 07:00AM RedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German Equity Forum (EKF) 2021
Nov 8, 2021 07:15AM RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
Nov 8, 2021 07:02AM RedHill Biopharma (RDHL) Announces Up to $10M Strategic Investment by Kukbo Co at 20% Premium to Market
Nov 8, 2021 07:00AM RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
Oct 25, 2021 07:02AM Redhill Biopharma Ltd (REDIF) Reports New Talicia and Movantik Data Analyses
Oct 25, 2021 07:01AM RedHill Biopharma Presents New Talicia® and Movantik® Data Analyses at ACG 2021
Oct 20, 2021 07:00AM RedHill Biopharma to Present at the BIO-Europe 2021 Conference
Oct 18, 2021 07:02AM RedHill Biopharma Announces Insider Buying
Oct 18, 2021 07:01AM RedHill Biopharma (RDHL) Announces 180,000 Share Insider Buy
Oct 18, 2021 07:00AM RedHill Biopharma Announces Insider Buying
Oct 12, 2021 07:02AM Redhill Biopharma (REDIF) Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
Oct 12, 2021 07:00AM RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034
Oct 6, 2021 07:01AM RedHill Biopharma (RDHL) Announces Talicia added to Medi-Cal Contract Drug List with No Prior Authorization Requirements
Oct 6, 2021 07:00AM RedHill Biopharma's Talicia® added to Medi-Cal Contract Drug List with No Prior Authorization Requirements
View More Recent Stories View Older Stories